Dossier assessment

Bempedoic acid/ezetimibe (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A20-91
Last updated

Report documents

  1. Extract of dossier assessment

    Bempedoic acid/ezetimibe (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 381 kB, EN, not accessible
  2. Dossier assessment

    Bempedoic acid/ezetimibe (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 315 kB, DE, not accessible

Dossier assessment

Indication:

Adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia

Result of dossier assessment:

Added benefit not proven in either of both research questions (drug and dietary lipid-lowering options not exhausted/exhausted except for evolocumab)

Project details

Project no.
A20-91
Commission
Commission awarded on 30.10.2020 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Digestion, metabolism and hormones
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relvant page of the GBA website.

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form